HomeCompareRHBAF vs ABBV

RHBAF vs ABBV: Dividend Comparison 2026

RHBAF yields 10.21% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RHBAF wins by $500026.95M in total portfolio value
10 years
RHBAF
RHBAF
● Live price
10.21%
Share price
$1.22
Annual div
$0.12
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$500027.05M
Annual income
$490,790,288,288.21
Full RHBAF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — RHBAF vs ABBV

📍 RHBAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRHBAFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RHBAF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RHBAF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RHBAF
Annual income on $10K today (after 15% tax)
$867.63/yr
After 10yr DRIP, annual income (after tax)
$417,171,745,044.98/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, RHBAF beats the other by $417,171,723,988.97/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RHBAF + ABBV for your $10,000?

RHBAF: 50%ABBV: 50%
100% ABBV50/50100% RHBAF
Portfolio after 10yr
$250013.57M
Annual income
$245,395,156,529.98/yr
Blended yield
98.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

RHBAF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
0.1
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RHBAF buys
0
ABBV buys
0
No recent congressional trades found for RHBAF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRHBAFABBV
Forward yield10.21%3.06%
Annual dividend / share$0.12$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$500027.05M$102.3K
Annual income after 10y$490,790,288,288.21$24,771.77
Total dividends collected$499402.32M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: RHBAF vs ABBV ($10,000, DRIP)

YearRHBAF PortfolioRHBAF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$12,741$2,041.48$11,550$430.00+$1.2KRHBAF
2$18,495$4,861.95$13,472$627.96+$5.0KRHBAF
3$32,982$13,191.63$15,906$926.08+$17.1KRHBAF
4$79,260$43,969.84$19,071$1,382.55+$60.2KRHBAF
5$282,316$197,507.74$23,302$2,095.81+$259.0KRHBAF
6$1,617,033$1,314,955.16$29,150$3,237.93+$1.59MRHBAF
7$15,808,209$14,077,983.73$37,536$5,121.41+$15.77MRHBAF
8$274,161,810$257,247,025.37$50,079$8,338.38+$274.11MRHBAF
9$8,632,485,260$8,339,132,123.86$69,753$14,065.80+$8632.42MRHBAF
10$500,027,047,516$490,790,288,288.21$102,337$24,771.77+$500026.95MRHBAF

RHBAF vs ABBV: Complete Analysis 2026

RHBAFStock

RHB Bank Berhad provides commercial banking and finance related products and services in Malaysia and internationally. Its Group Community Banking segment offers mortgages, non-residential mortgages, hire purchase, purchase of securities, credit cards, other personal loans, financing, remittance, deposits collection, investment related, and bancassurance/bancatakaful products to individual customers; financing solutions to SMEs and family-owned enterprises, as well as trade and cash management solutions for SMEs. The company's Group Wholesale Banking segment provides treasury products and solutions; advisory services, such as corporate and debt restructuring, mergers and acquisitions, takeovers, as well as fundraising services for institutional and retail clients; stockbroking and investment banking products and services; management of unit trust funds, investment management advisory, private mandates, product development, and trustee services; financing, deposits, cash management, trade finance, FX and remittance services; and supply chain financing solutions. Its Group International Business segment offers commercial banking related products and services in Singapore, Thailand, Brunei, Cambodia, and Lao. The company's Insurance segment provides general insurance for retail, SME, commercial, and corporate customers. Its Support Center and Others segment offers nominee, property investment and rental of premises, and other related financial services. The company also provides Islamic banking, leasing, offshore trust, general insurance, and custodian services, as well as fiduciary services. In addition, it offers corporate secretarial services; leasing of industrial construction, business equipment, and motor vehicles; private equity investment; securities dealing and margin financing; dealing in futures and options contracts; securities brokerage and underwriting; and property management. RHB Bank Berhad is based in Kuala Lumpur, Malaysia.

Full RHBAF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this RHBAF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RHBAF vs SCHDRHBAF vs JEPIRHBAF vs ORHBAF vs KORHBAF vs MAINRHBAF vs JNJRHBAF vs MRKRHBAF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.